Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3384) 3384
Publication (436) 436
Book Chapter (45) 45
Book Review (13) 13
Dissertation (9) 9
Conference Proceeding (5) 5
Book / eBook (2) 2
Data Set (2) 2
Newspaper Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1958) 1958
index medicus (1401) 1401
cd38 (1383) 1383
male (953) 953
female (924) 924
cd38 expression (913) 913
hematology (881) 881
cd38 antigen (806) 806
middle aged (736) 736
adult (679) 679
oncology (667) 667
flow cytometry (631) 631
animals (589) 589
immunology (582) 582
aged (577) 577
prognosis (563) 563
leukemia, lymphocytic, chronic, b-cell - genetics (436) 436
adp-ribosyl cyclase (417) 417
chronic lymphocytic leukemia (400) 400
expression (398) 398
adp-ribosyl cyclase 1 (381) 381
biochemistry & molecular biology (373) 373
cyclic adp-ribose (372) 372
survival (367) 367
lymphocytes (363) 363
mice (351) 351
activation (349) 349
disease progression (345) 345
membrane glycoproteins (340) 340
aged, 80 and over (333) 333
cell biology (323) 323
apoptosis (307) 307
leukemia, lymphocytic, chronic, b-cell - pathology (304) 304
cancer (303) 303
adp-ribosyl cyclase 1 - metabolism (283) 283
cll (281) 281
lymphocytes t (280) 280
cells (277) 277
analysis (264) 264
leukemia (256) 256
medicine (245) 245
mutation (243) 243
gene expression (238) 238
zap-70 expression (238) 238
genomic aberrations (235) 235
multiple myeloma (231) 231
patients (229) 229
antigens, cd (227) 227
leukemia, lymphocytic, chronic, b-cell - diagnosis (226) 226
disease (224) 224
signal transduction (217) 217
research (216) 216
immunophenotyping (215) 215
research article (209) 209
hiv infections - immunology (205) 205
b-cells (201) 201
hemic and lymphatic diseases (201) 201
multidisciplinary sciences (201) 201
t cells (201) 201
hiv (200) 200
leukemia, lymphocytic, chronic, b-cell - immunology (198) 198
infectious diseases (197) 197
cd4 antigen (196) 196
leukemia, lymphocytic, chronic, b-cell - metabolism (195) 195
variable-region mutations (194) 194
nad (191) 191
pathology (191) 191
cells, cultured (188) 188
chronic lymphocytic-leukemia (187) 187
cell activation (185) 185
science (185) 185
zap-70 (184) 184
adp-ribosyl cyclase 1 - genetics (183) 183
differentiation (183) 183
lymphocytes b (178) 178
immunoglobulin heavy chains - genetics (176) 176
cd8 antigen (173) 173
health aspects (172) 172
medicine, research & experimental (172) 172
proteins (168) 168
cytokines (167) 167
leukemia, lymphocytic, chronic, b-cell - mortality (167) 167
gene mutation status (162) 162
therapy (162) 162
article (161) 161
diagnosis (161) 161
immunoglobulin variable region - genetics (161) 161
antigens (159) 159
stem cells (158) 158
histocompatibility antigen hla (157) 157
inflammation (155) 155
phenotype (154) 154
bone marrow (153) 153
genetic aspects (152) 152
care and treatment (150) 150
t-cells (149) 149
human immunodeficiency virus--hiv (147) 147
immune activation (147) 147
lymphocyte activation (144) 144
calcium - metabolism (142) 142
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3343) 3343
French (13) 13
Japanese (13) 13
Polish (12) 12
Russian (10) 10
Chinese (8) 8
Spanish (7) 7
German (5) 5
Czech (3) 3
Turkish (3) 3
Hungarian (2) 2
Korean (2) 2
Italian (1) 1
Persian (1) 1
Portuguese (1) 1
Romanian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
by Palumbo, Antonio and Chanan-Khan, Asher and Weisel, Katja and Nooka, Ajay K and Masszi, Tamas and Beksac, Meral and Spicka, Ivan and Hungria, Vania and Munder, Markus and Mateos, Maria V and Mark, Tomer M and Qi, Ming and Schecter, Jordan and Amin, Himal and Qin, Xiang and Deraedt, William and Ahmadi, Tahamtan and Spencer, Andrew and Sonneveld, Pieter and CASTOR Investigators
The New England Journal of Medicine, ISSN 0028-4793, 08/2016, Volume 375, Issue 8, pp. 754 - 766
In a study involving patients with refractory multiple myeloma, the anti-CD38 antibody daratumumab in combination with bortezomib and dexamethasone resulted in... 
TRIAL | ANTIBODY DARATUMUMAB | MEDICINE, GENERAL & INTERNAL | CD38 | PHASE-2 | MONOTHERAPY | Recurrence | Dexamethasone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Dexamethasone - adverse effects | Drug Resistance, Neoplasm | Male | ADP-ribosyl Cyclase 1 - antagonists & inhibitors | Disease-Free Survival | Multiple Myeloma - drug therapy | Bortezomib - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Adult | Female | Aged | Infusions, Intravenous | Care and treatment | Usage | Bortezomib | Dexamethasone | Diagnosis | Multiple myeloma | Thrombocytopenia | Body weight | CD38 antigen | Monoclonal antibodies | Cytotoxicity | Drug therapy | Survival | Patients | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial
by Ensoli, Fabrizio and Cafaro, Aurelio and Casabianca, Anna and Tripiciano, Antonella and Bellino, Stefania and Longo, Olimpia and Francavilla, Vittorio and Picconi, Orietta and Sgadari, Cecilia and Moretti, Sonia and Cossut, Maria Pavone R and Arancio, Angela and Orlandi, Chiara and Sernicola, Leonardo and Maggiorella, Maria T and Paniccia, Giovanni and Mussini, Cristina and Lazzarin, Adriano and Sighinolfi, Laura and Palamara, Guido and Gori, Andrea and Angarano, Gioacchino and Di Pietro, Massimo and Galli, Massimo and Mercurio, Vito S and Castelli, Francesco and Di Perri, Giovanni and Monini, Paolo and Magnani, Mauro and Garaci, Enrico and Ensoli, Barbara
Retrovirology, ISSN 1742-4690, 04/2015, Volume 12, Issue 1, p. 33
Background: The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials. gov NCT00751595) was aimed at evaluating the... 
HIV-1 | Tat protein | Proviral DNA | HLA-DR | CD8 | Antibodies | CD38 | Vaccine | T cells | HAART | Neutralization | VIRAL LOAD | DENDRITIC CELLS | PERIPHERAL-BLOOD | VIROLOGY | KAPOSIS-SARCOMA | T-CELL-ACTIVATION | ACTIVE ANTIRETROVIRAL THERAPY | TERM-FOLLOW-UP | CYNOMOLGUS MONKEYS | CD38(+)HLA-DR+/CD8(+) T cells | INFLUENZA VACCINE | DISEASE PROGRESSION | HIV Antibodies - blood | Follow-Up Studies | Immunoglobulin G - blood | Humans | Middle Aged | AIDS Vaccines - immunology | Acquired Immunodeficiency Syndrome - therapy | Male | Treatment Outcome | CD4 Lymphocyte Count | AIDS Vaccines - adverse effects | Viral Load | Leukocytes - immunology | Young Adult | Acquired Immunodeficiency Syndrome - immunology | Immunoglobulin M - blood | Adult | Female | Italy | tat Gene Products, Human Immunodeficiency Virus - immunology | AIDS Vaccines - administration & dosage | Antiretroviral Therapy, Highly Active - methods | Antibodies, Neutralizing - blood | Antiviral agents | Dendritic cells | Lymphocytes | Vaccination | DNA | Clinical trials | Homeostasis | HIV (Viruses)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Daratumumab in multiple myeloma
by Nooka, Ajay K and Kaufman, Jonathan L and Hofmeister, Craig C and Joseph, Nisha S and Heffner, Thomas L and Gupta, Vikas A and Sullivan, Harold C and Neish, Andrew S and Dhodapkar, Madhav V and Lonial, Sagar
Cancer, ISSN 0008-543X, 07/2019, Volume 125, Issue 14, pp. 2364 - 2382
The development of effective monoclonal antibodies for the treatment of myeloma has been a long journey of clinical and drug development. Identification of the... 
infusion reactions | myeloma | daratumumab | myeloma management | CD38 monoclonal antibody | CELLS | DEXAMETHASONE | COMPLEMENT | MONOTHERAPY | MECHANISMS | BORTEZOMIB | POMALIDOMIDE | ONCOLOGY | LENALIDOMIDE | CD38 EXPRESSION | INTERFERENCE | Antigens | Refractory materials | Target recognition | CD38 antigen | Multiple myeloma | Clinical trials | Monoclonal antibodies | Drug development | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Immunomodulatory effects of CD38-targeting antibodies
by van de Donk, NWCJ
IMMUNOLOGY LETTERS, ISSN 0165-2478, 07/2018, Volume 199, pp. 16 - 22
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of... 
MULTIPLE-MYELOMA | Adenosine | EFFICACY | PD-1 BLOCKADE | Multiple myeloma | IMMUNOLOGY | ANTITUMOR-ACTIVITY | CELL-DEATH | TARGETING CD38 | MICROENVIRONMENT | Daratumumab | Monoclonal antibodies | CD38 | CD38 EXPRESSION | NIVOLUMAB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
by Costa, Federica and Toscani, Denise and Chillemi, Antonella and Quarona, Valeria and Bolzoni, Marina and Marchica, Valentina and Vescovini, Rosanna and Mancini, Cristina and Martella, Eugenia and Campanini, Nicoletta and Schifano, Chiara and Bonomini, Sabrina and Accardi, Fabrizio and Horenstein, Alberto L and Aversa, Franco and Malavasi, Fabio and Giuliani, Nicola
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 34, pp. 56598 - 56611
It is known that multiple myeloma (MM) cells express CD38 and that a recently developed human anti-CD38 monoclonal antibody Daratumumab mediates myeloma... 
CD38 | Bone disease | Osteoclast | Immunotherapy | Multiple myeloma | MULTIPLE-MYELOMA | multiple myeloma | ADP-RIBOSYL CYCLASE | MARROW | MECHANISM | RECEPTOR | ECTOENZYMES | CELL BIOLOGY | TARGETING CD38 | CD38/ADP-RIBOSYL CYCLASE | immunotherapy | LENALIDOMIDE | CELLS EXPRESS | osteoclast | bone disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Daratumumab for the treatment of multiple myeloma
by Plesner, Torben and Krejcik, Jakub
Frontiers in Immunology, ISSN 1664-3224, 06/2018, Volume 9, p. 1228
This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma. 
Adenosine | Immunomodulation | Daratumumab | CD38 | Complement | Myeloma | Neonatal Fc-receptors | Trogocytosis | trogocytosis | immunomodulation | DEXAMETHASONE | MONOTHERAPY | BORTEZOMIB | IMMUNOLOGY | PLASMA-CELLS | adenosine | TARGETING CD38 | myeloma | THERAPY | CLINICAL-EFFICACY | LENALIDOMIDE | CD38 EXPRESSION | INTERFERENCE | daratumumab | complement | neonatal Fc-receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD super(+) catabolizing enzyme
by Kuhn, Isabelle and Kellenberger, Esther and Said-Hassane, Fatouma and Villa, Pascal and Rognan, Didier and Lobstein, Annelise and Haiech, Jacques and Hibert, Marcel and Schuber, Francis and Muller-Steffner, Helene
Bioorganic and Medicinal Chemistry, ISSN 0968-0896, 11/2010, Volume 18, Issue 22, pp. 7900 - 7910
Schistosomiasis is a major tropical parasitic disease. For its treatment, praziquantel remains the only effective drug available and the dependence on this... 
CD38 antigen
Journal Article
Details down arrow
8. Full Text Retinal differentiation of human bone marrow-derived stem cells by co-culture with retinal pigment epithelium in vitro
by Mathivanan, Isai and Trepp, Carolyn and Brunold, Claudio and Baerlocher, Gabriela and Enzmann, Volker
Experimental Cell Research, ISSN 0014-4827, 04/2015, Volume 333, Issue 1, pp. 11 - 20
The goal of this study was to assess the differentiation capacity of human bone marrow-derived stem cells (hBMSCs) along retinal lineages. Mononuclear cells... 
Bone marrow-derived stem cells | Retinal pigment epithelial cells | Human | Differentiation | In vitro | CD34+CD38 | CD38 | CD34 | SUBPOPULATIONS | COLONY-STIMULATING FACTOR | RPE | PHENOTYPE | MACULAR DEGENERATION | PERIPHERAL-BLOOD | TRANSPLANTATION | CELL BIOLOGY | CD34(+)CD38(+) | HEMATOPOIETIC PROGENITOR CELLS | CD34(+)CD38(-) | ONCOLOGY | GENE-EXPRESSION | STROMAL CELLS | Adult Stem Cells - physiology | Gene Expression | Coculture Techniques | Humans | Cells, Cultured | Retinal Pigment Epithelium - physiology | Bone Marrow Cells - physiology | Cell Differentiation | Phagocytosis | Ophthalmology | Gene expression | Analysis | Stem cells | Studies | Bone marrow | Cellular biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A cytosolic chaperone complex controls folding and degradation of type III CD38
by Wu, Yang and Zhang, Jingzi and Fang, Lei and Lee, Hon Cheung and Zhao, Yong Juan
Journal of Biological Chemistry, ISSN 0021-9258, 2019, Volume 294, Issue 11, pp. 4247 - 4258
Cluster of differentiation 38 (CD38) is the best-studied enzyme catalyzing the synthesis of the Ca2+ messenger cyclic ADP-ribose. It is a single-pass... 
CYCLIC ADP-RIBOSE | HSP90 | ACTIVATION | cyclic ADP ribose (cADPR) | heat shock protein 90 (Hsp90) | lysosomal degradation | Hsp70-interacting protein (Hip) | BIOCHEMISTRY & MOLECULAR BIOLOGY | cytosolic soluble CD38 | HYDROLYSIS | MATURATION | HIP | heat shock protein (HSP) | HEAT-SHOCK-PROTEIN | hsp70 | INHIBITION | chaperone | CD38 | protein folding | EXPRESSION | protein degradation | type III CD38 | ADP-ribosyl Cyclase 1 - metabolism | Cytosol - metabolism | Membrane Glycoproteins - metabolism | Humans | Protein Folding | HEK293 Cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Reprint of "Immunomodulatory effects of CD38-targeting antibodies"
by van de Donk, NWCJ
IMMUNOLOGY LETTERS, ISSN 0165-2478, 01/2019, Volume 205, pp. 71 - 77
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of... 
MULTIPLE-MYELOMA | Adenosine | PD-1 BLOCKADE | Multiple myeloma | IMMUNOLOGY | ANTITUMOR-ACTIVITY | IMMUNE CHECKPOINT | CELL-DEATH | TARGETING CD38 | MICROENVIRONMENT | Daratumumab | Monoclonal antibodies | CD38 | CD38 EXPRESSION | NIVOLUMAB | Medical research | Immune response | Biological products | Analysis | Immunotherapy | Medicine, Experimental | B cells | T cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Papain‐treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti‐CD38‐based therapies
by Carreño‐Tarragona, G and Cedena, T and Montejano, L and Alonso, R and Miras, F and Valeri, A and Rivero, A and Lahuerta, J. J and Martinez‐Lopez, J
Transfusion Medicine, ISSN 0958-7578, 06/2019, Volume 29, Issue 3, pp. 193 - 196
SUMMARY Objectives To report our 2 years of experience navigating the interference of anti‐CD38 monoclonal antibodies (MAs) in 33 patients and describe... 
anti‐CD38 therapies | multiple myeloma | alloantibody identification | transfusion | interference | TARGETING CD38 | DARATUMUMAB INTERFERENCE | ANTIBODY | anti-CD38 therapies | HEMATOLOGY | Care and treatment | Digital television | Multiple myeloma | Papain | Blood banks | Blood transfusion | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Reprint of “Immunomodulatory effects of CD38-targeting antibodies”
by van de Donk, Niels W.C.J
Immunology Letters, ISSN 0165-2478, 01/2019, Volume 205, pp. 71 - 77
The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of... 
Monoclonal antibodies | CD38 | Adenosine | Daratumumab | Multiple myeloma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Influence of GB virus C on IFN-y and IL-2 production and CD38 expression in T lymphocytes from chronically HIV-infected and HIV-HCV-co-infected patients
by Baggio-Zappia, Giovana Loticis and Barbosa, Aline de Jesus and Coló Brunialti, Milena Karina and Salomão, Reinaldo and Hernandes Granato, Celso Francisco
01/2012
This study was designed to assess the effect of GB virus (GBV)-C on the immune response to human immunodeficiency virus (HIV) in chronically HIV-infected and... 
Tγδ | HIV | immune activation | GBV-C/HGV | CD38 | cytokines
Web Resource
Details down arrow
14. Full Text Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon‐α and ATRA
by Bat‐Erdene, Ariunzaya and Nakamura, Shingen and Oda, Asuka and Iwasa, Masami and Teramachi, Jumpei and Ashtar, Mohannad and Harada, Takeshi and Miki, Hirokazu and Tenshin, Hirofumi and Hiasa, Masahiro and Fujii, Shiro and Sogabe, Kimiko and Oura, Masahiro and Udaka, Kengo and Kagawa, Kumiko and Yoshida, Sumiko and Aihara, Ken‐ichi and Kurahashi, Kiyoe and Endo, Itsuro and Abe, Masahiro
British Journal of Haematology, ISSN 0007-1048, 06/2019, Volume 185, Issue 5, pp. 969 - 974
CD38 | multiple myeloma | HDAC inhibition | ATRA | interferon‐α | interferon-α | RESISTANCE | interferon-alpha | TRANS-RETINOIC ACID | HEMATOLOGY | UP-REGULATION | EXPRESSION | CHAPERONE FUNCTION | Histone deacetylase | Interferon | Myeloma | CD38 antigen
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH)
by Bock, Karl Walter
Biochemical Pharmacology, ISSN 0006-2952, 11/2019, Volume 169, p. 113620
Aryl hydrocarbon receptor (AHR), identified in studies of dioxin toxicity, has been characterized as ligand-activated transcription factor involved in diverse... 
NASH | AHR, CD38, NAD metabolism | Hepatic steatosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism
by Matalonga, Jonathan and Glaria, Estibaliz and Bresque, Mariana and Escande, Carlos and Carbó, José María and Kiefer, Kerstin and Vicente, Ruben and León, Theresa E and Beceiro, Susana and Pascual-García, Mónica and Serret, Joan and Sanjurjo, Lucía and Morón-Ros, Samantha and Riera, Antoni and Paytubi, Sonia and Juarez, Antonio and Sotillo, Fernando and Lindbom, Lennart and Caelles, Carme and Sarrias, Maria-Rosa and Sancho, Jaime and Castrillo, Antonio and Chini, Eduardo N and Valledor, Annabel F
Cell Reports, ISSN 2211-1247, 01/2017, Volume 18, Issue 5, pp. 1241 - 1255
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to... 
NAD | cytoskeleton | LXR | macrophage | nuclear receptor | CD38 | bacterial infection | CELLS | LIPID-METABOLISM | INTERFERON-GAMMA | INFLAMMATORY RESPONSES | IFN-GAMMA | INNATE IMMUNE-RESPONSE | PPAR-GAMMA | CD38 EXPRESSION | DEPENDENT GENE-EXPRESSION | LIVER-X-RECEPTORS | CELL BIOLOGY | Cell Line | Actin Cytoskeleton - metabolism | Salmonella typhimurium - pathogenicity | Cercopithecus aethiops | Male | Liver X Receptors - metabolism | Salmonella Infections - metabolism | Macrophages - metabolism | Animals | ADP-ribosyl Cyclase 1 - metabolism | Female | RAW 264.7 Cells | Mice | COS Cells | NAD - metabolism | Receptors, Cytoplasmic and Nuclear - metabolism | Receptors nuclears (Bioquímica) | Cytoskeleton | Citosquelet | Macròfags | Macrophages | Nuclear receptors (Biochemistry)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights